Entinostat (MS-275)

Catalog No.S1053 Synonyms: SNDX-275

Entinostat (MS-275) Chemical Structure

Molecular Weight(MW): 376.41

Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.

Size Price Stock Quantity  
In DMSO USD 91 In stock
USD 70 In stock
USD 150 In stock
USD 270 In stock
USD 770 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 63 Publications

14 Customer Reviews

  • (A) U87 cells were cultured in the presence of DMSO, 1 uM MS-275 alone, 100 ng/ml IFN-λ1 alone, or both for the course of 4 d. Cell numbers were manually determined by hemacytometer counting at the indicated time points. (B, F) Cell proliferation of U87 cells or U87 spheroids in 3D culture with indicated treatment were performed using the WST-1 assay, which measures active cellular metabolism. (C) U87 spheroid formation in 3D culture was photographed at day 14 in culture (representative images are shown; 200x magnification). (D-E) Quantification of the relative sizes and numbers of U87 spheroids in (C). (G) Cell cycle analysis was performed in U87 cells with indicated treatment using propidium iodide staining. Numbers in the histogram show fractions (percent) of sub-G1, N, 2N, and polyploidy from left to right. (H) U87 cells with indicated treatment were stained with Annexin V-FITC and 7-AAD. Numbers indicate the percentage of FITC-positive cells (upper left quadrant). FITC, fluorescein isothiocyanate; 7-AAD, 7-Aminoactinomycin. In all panels, data represent the mean and SEM of at least three experiments.

    PLoS Biol 2014 12, e1001758. Entinostat (MS-275) purchased from Selleck.

    Inhibition of HDAC1-mediated DNMT1 deacetylation promotes DNMT1 proteasomal degradation. (A) Knockout of HAUSP potentiates HDAC inhibitor (HDACi)-induced DNMT1 degradation. Parental or HAUSP KO DLD1 cells were treated or not with 5 μM HDACi MS-275 for 72 hours and cell lysates were blotted with the indicated antibodies. (B) HDAC inhibition induces DNMT1 ubiquitination. HAUSP WT or KO cells were treated with or without HDACi for 24 hours and MG132 for 12 hours before being harvested to make cell lysates. DNMT1 immunoprecipitates were blotted with an antibody against ubiquitin. Because the abundance of DNMT1 in the HAUSP KO cells is lower than in WT cells, more KO cells were used than WT cells to obtain equal amounts of precipitated DNMT1 proteins. (C) DNMT1 is acetylated after HDACi treatment. DNMT1 immunoprecipitates from cells treated with HDACi were blotted with an antibody against acetylated lysine (Ac-K). (D) A DNMT1 acetylation site mutant is resistant to HDACi-induced degradation. HEK 293 cells were transfected with WT DNMT1 or a DNMT1 mutant lacking four known acetylation sites (K173R, K1113R, K115R, and K117R) and treated with MS-275 for 48 hours and with CHX for 24 hours. Cell lysates were blotted with the indicated antibodies. (E) Knockdown of HDAC1 decreases the abundance of DNMT1. RKO cells were treated with the indicated concentration of doxycycline (Dox) for 48 hours to induce expression of an shRNA directed against HDAC1. Western blots were performed with the indicated antibodies. (F) Knockdown of HDAC1 leads to increased acetylation of DNMT1. RKO cells expressing an inducible HDAC1 shRNA were treated with or without Dox (4 mg/ml) for 36 hours and then with MG132 for 12 hours. DNMT1 immunoprecipitates were blotted with an antibody against Ac-K. Cell lysates were also blotted with antibodies against HDAC1 and b-actin.

     

     

    Sci Signal 2010 3, ra80. Entinostat (MS-275) purchased from Selleck.

  • The E3 ligase UHRF1 ubiquitinates DNMT1. (A) HDAC inhibition enhances DNMT1 interaction with UHRF1. HEK 293 cells were transfected with plasmids expressing Myc-DNMT1 and Flag-UHRF1 and treated with or without MS-275 for 24 hours. Myc-DNMT1 immunoprecipitates were blotted with the indicated antibodies. (B and C) HDAC inhibition enhances the interaction of endogenous DNMT1 and UHRF1. Cells were treated with or without MS-275 and UHRF1 (B) or DNMT1 (C) immunoprecipitates were blotted with the indicated antibodies. (D) UHRF1 ubiquitinates DNMT1. HEK 293 cells were transfected with the indicated plasmids. Antibodies against Myc immunoprecipitates were blotted with antibody against HA to detect ubiquitinated DNMT1. Myc-DNMT1D, DNMT1 mutant lacking the HAUSP-interacting domain. UHRF1DRING, UHRF1 with a RING domain deletion. (E) Knockdown of UHRF1 blocks HDACi-induced DNMT1 degradation. HEK 293 cells were transfected with control siRNA or siRNAs against UHRF1 and treated with or without MS-275. Western blotting was performed with the indicated antibodies. (F) Overexpression of UHRF1 leads to degradation of a DNMT1 mutant lacking the HAUSP-interacting domain (DNMT1D). Full-length DNMT1 or DNMT1D was cotransfected into HEK 293 cells with the indicated expression vectors. Cell lysates were blotted with the indicated antibodies. (G) DNMT1, HAUSP, UHRF1, HDAC1, and PCNA associate with Tip60. Flag-tagged Tip60 immunoprecipitates were blotted with the indicated antibodies.

     

     

    Sci Signal 2010 3, ra80. Entinostat (MS-275) purchased from Selleck.

    HAUSP KO cells are more sensitive to HDACi-induced apoptosis.(A) HDAC inhibition induces apoptosis in HAUSP KO cells.HAUSP WT or KO cells were treated with or without MS-275 at the indicated concentration for 72 hours, then fixed and stained with propidium iodide. Flow cytometric analyses were used to profile sub-G1, G1, and G2-M cell populations. Apoptotic cells were quantified after the indicated clones were treated with either 5 or 10 μM MS-275. The means and SDs of three independent experiments were plotted (*P<0.001, t test). (B) HDAC inhibition induces apoptosis in HAUSP KO cells but leads to G2-M arrest in WT cells.Cell cycle profiles of HAUSP WT or KOcells that were treated or not with 5 μM MS-275. (C)HDAC inhibition increases the abundance of apoptotic cell markers. The indicated cells were treated with or without MS-275 for 72 hours.Cell lysates were blotted with antibodies against cleaved caspase 3 and β-actin. (D) Ectopic overexpression of DNMT1 in HAUSP KO cells suppresses apoptosis. HAUSP KO clones or HAUSP KO cells inducibly

    overexpressingDNMT1 were treatedwith 10 μM MS-275. Apoptotic cell populations were quantified by fluorescence-activated cell sorting (FACS) analyses (*P < 0.001, t test). Cell lysates from these cells were blotted with the indicated antibodies. (E) HDAC inhibition arrests the growth of HAUSP KO cells. DLD1, HAUSP KO, and KO cells ectopically expressing HAUSP were treated with the indicated concentration of MS-275 for 4 days. Cell numbers were determined and data from eight replicates were plotted (**P <0.001, t test). (FandG) HDACi inhibits tumor xenograft formation ofHAUSP KOcells.Athymic nudemice (five in each group)were injectedsubcutaneously and bilaterallywith cells of the indicated genotypes. Mice were treated with or without MS-275 at 15mg/kg for 4 weeks. Tumors were harvested and photographed (F). Tumor sizes of the indicated groupsweremeasuredweekly and theaveragevolumes at each timepoint were plotted (G).MANOVA analyses were performed to determine whether there was an overall difference of the tumor sizes, as well as whether there was a difference in development over time of tumor sizes between the two groups (P < 0.0001).
     

     

    Sci Signal 2010 3, ra80. Entinostat (MS-275) purchased from Selleck.

  • Numerous APC (+) oligodendrocytes (middle upper panel) with ellipsoid nuclei labeled with Sytox (left upper panel) were observed in 8 week old Thy-1 mitoCFP control MONs. NF-200 (+) neurofilaments extended along the MON as linear individual fibers (right upper panel). A period of OGD (60 min) caused a significant loss of APC (+) oligodendrocytes, a gain in the appearance of pyknotic nuclei (dense, brighter nuclei, white arrows, OGD panel), and loss of NF-200 (+) axon structures, which were, replaced with axonal head and bulb formation (white asterisks). Pretreatment with SAHA (1uM) or MS-275 (1uM) effectively preserved APC (+) oligodendrocytes, together with numerous linear individual NF-200 (+) axons. Note fewer pyknotic nuclei (white arrows, SAHA and MS-275 panels) after OGD in MONs treated with SAHA or MS-275.

    J Neurosci 2011 31, 3990-9. Entinostat (MS-275) purchased from Selleck.

    Notch1ICD, Notch2ICD, and Notch3ICD were transduced into human aortic SMCs, which were then treated with HDAC inhibitors TSA or MS-275 or with vehicle DMSO (con). The top 2 rows are different exposures of the same blot to detect the epitope tags on the N ICD constructs. Longer (top row) and shorter ( second row) exposures are shown because t he level of N2ICD expression was lower than that of N1ICD and N3ICD. SMC markers were analyzed and were similarly induced by activation of each Notch r eceptor. Both TSA and MS-275 significantly suppressed the induction of SMC proteins by Notch activation.

    J Am Heart Assoc 2012 1, e000901. Entinostat (MS-275) purchased from Selleck.

  • LSD1 and HDAC inhibitors exhibit synergistic growth inhibition. Cells were simultaneously treated with pargyline or HDAC inhibitors for 48 h.

     

     

    Breast Cancer Res Treat 2012 131, 777-789. Entinostat (MS-275) purchased from Selleck.

    Histone acetylation in the spinal cord after HDACI treatment. Histone acetylation in the lumbar spinal cord of mice receiving i.t. SAHA (25 μg) or MS-275 (0.5 μg) for 30 min was analyzed by immunoblot (A, B) and immunofluorescent histochemistry (C) for antigens indicated. Animals receiving i.t. saline were used as control. Images of the H3K9/18ac signals in the left half of the lumbar spinal cord are shown in the first row in C. Immunosignals of indicated antigens in the superficial dorsal horn are presented in the rest rows in C.

    Mol Pain 2010 6, 51. Entinostat (MS-275) purchased from Selleck.

  • B. Confluent quiescent foreskin fibroblasts were treated with HDAC1 inhibitor or vehicle for 24 hours. Type I procollagen protein levels in whole cell lysates were determined by immunoblotting. A representative result of three independent experiments is shown. The band density was evaluated by densitometry. C. Under the same conditions, mRNA levels of the α1(I) collagen (COL1A1) gene were determined using reverse transcription quantitative real-time PCR. The graph represents -fold change in COL1A1 mRNA levels in comparison to unstimulated controls, which were arbitrarily set at 100. The mean and SD from three separate experiments are shown. * p<0.05 versus control cells treated with vehicle.

    PLoS One 2013 8, e74930. Entinostat (MS-275) purchased from Selleck.

    Inhibition of LSD1 activity by HDAC inhibitors. a MDA-MB-231 and MDA-MB-468 cells were exposed to indicated HDAC inhibitors for 24 h.

     

     

    Exp Dermatol 2010 19, 1096-1102. Entinostat (MS-275) purchased from Selleck.

  • HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h, and their expression of GRP78, PERK-eIF2α axis and ATF4, ATF3, CHOP and DR5 proteins.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Entinostat (MS-275) purchased from Selleck.

    HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h. ATF4, ATF3, CHOP and DR5 proteins were measured by Western blot.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Entinostat (MS-275) purchased from Selleck.

  •  

    HDAC inhibition increases SMN-luciferase reporter mRNA levels. qRT-PCR was used to measure increases of SMN-luciferase mRNA following treatment with HDAC inhibitors. Fold increase of mRNA was normalized to GAPDH.

    Biochem Bioph Res Co 2010 414, 25-30. Entinostat (MS-275) purchased from Selleck.

    Western blot analysis of Acetyl-H3 and H3. 0-20μM MS-275 was added.

     

     

    2011 Dr. Zhang of Tianjin Medical University. Entinostat (MS-275) purchased from Selleck.

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.
Targets
HDAC1 [2]
(Cell-free assay)
HDAC3 [2]
(Cell-free assay)
0.51 μM 1.7 μM
In vitro

MS-275 shows inhibitory to HDACs by 2'-amino group. MS-275 induces accumulation of p21WAF1/CIP1 and gelsolin in K562 cell. MS-275 could reduce S-phase cells and induce G1-phase cells in A2780 cell. MS-275 inhibits the proliferation of human tumor cell lines including A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 with IC50 from 41.5 nM to 4.71 μM, which due to HAD-inhibition. [1] MS-275 is not sensitive to other HDACs (4, 6, 8 and 10) with IC50 about/above 100 μM. [2] MS-275 shows great inhibition to human leukemia and lymphoma cells, including U937, HL-60, K562, and Jurkat. MS-275 also decreases expression of cyclin D1 and the antiapoptotic proteins Mcl-1 and XIAP. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SCC-3 NIDacWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvwWGdKSzVyPUCuNFYyKM7:TR?= M2LmfHNCVkeHUh?=
ALL-PO NEm0cpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HpSmlEPTB;MD6wOlM2PSEQvF2= M4jDenNCVkeHUh?=
697 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\QOYZSUUN3ME2wMlA6QTd4IN88US=> NVfMWZdOW0GQR1XS
NCI-H748 MkTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\BPHJKSzVyPUCuNVA{OzRizszN NFH3VYxUSU6JRWK=
NKM-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTBwMUC5NVIh|ryP M3m4UHNCVkeHUh?=
ES1 NIO2cYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEH4UGtKSzVyPUCuNVEzPTVizszN NUnPVIJJW0GQR1XS
NCI-H1963 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXuTWM2OD1yLkGxOVc6KM7:TR?= MXzTRW5ITVJ?
NCI-H1417 NIDTZXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nSWWlEPTB;MD6xNlk4PCEQvF2= M1HYfHNCVkeHUh?=
NEC8 NF3I[pZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nzOWlEPTB;MD6xN|UzPyEQvF2= NWOwboZuW0GQR1XS
CRO-AP2 NFXybYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXrZ|lKSzVyPUCuNVY5QDlizszN NXfkW3hOW0GQR1XS
A3-KAW M{DjdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPLTWM2OD1yLkG3OlI4KM7:TR?= NFTyVINUSU6JRWK=
SF539 NVLKSm9jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrOXIhMUUN3ME2wMlE6PTl|IN88US=> MlrzV2FPT0WU
NOS-1 M{iyXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXXTWM2OD1yLkG5OlE6KM7:TR?= NVPZfpR2W0GQR1XS
NTERA-S-cl-D1 NIDEVFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TTdmlEPTB;MD6yNFEyOyEQvF2= Mn2wV2FPT0WU
COR-L88 M{DXcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfKTWM2OD1yLkKyPVU6KM7:TR?= NFjmcGdUSU6JRWK=
EM-2 MoewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3q0R2lEPTB;MD6yOFA4QSEQvF2= NFuwSHBUSU6JRWK=
KARPAS-45 NWnhWGlsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfqTWM2OD1yLkK3PFM{KM7:TR?= MnLMV2FPT0WU
DSH1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nuVGlEPTB;MD6yPFcxQCEQvF2= MmXyV2FPT0WU
HT-144 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHOweXdKSzVyPUCuN|AzPTZizszN MVHTRW5ITVJ?
ATN-1 NEnzR|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI[yfXNKSzVyPUCuN|A2PzZizszN NY\6XYN7W0GQR1XS
HEL M2r6O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{GyeGlEPTB;MD6zNVM1QCEQvF2= MWHTRW5ITVJ?
NB12 MoXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTBwM{G3OVYh|ryP M3HFOHNCVkeHUh?=
LU-139 NXvBUWNET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXWzT2lkUUN3ME2wMlM{PTFizszN M4fV[XNCVkeHUh?=
J-RT3-T3-5 NXvGOopwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M32xT2lEPTB;MD6zN|cyPiEQvF2= M3q0c3NCVkeHUh?=
MOLT-13 NVPq[3d5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PucGlEPTB;MD6zN|gyKM7:TR?= NGPKWHdUSU6JRWK=
SR NX3TZ2ZtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvKTWM2OD1yLkO0NlYyKM7:TR?= Mn60V2FPT0WU
CMK NGPM[2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIW0Um9KSzVyPUCuN|U4OjdizszN NFq3[FJUSU6JRWK=
ES8 MoLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTBwM{[wNlIh|ryP Mk\pV2FPT0WU
LB647-SCLC M1u2O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;Ob2lEPTB;MD6zOlc{KM7:TR?= MVTTRW5ITVJ?
TE-8 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjGNFhKSzVyPUCuN|Y6OzVizszN MUTTRW5ITVJ?
BV-173 Ml\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrhTWM2OD1yLkO3NVIyKM7:TR?= NX\TWY9MW0GQR1XS
DEL M{LNcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHBe2FKSzVyPUCuN|c1QDdizszN MV7TRW5ITVJ?
ARH-77 NFjNZoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITiSFBKSzVyPUCuN|gyQTNizszN M1:5SXNCVkeHUh?=
NCCIT NGnUZ3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEGzPXFKSzVyPUCuN|g3PDlizszN M3vYR3NCVkeHUh?=
RPMI-8402 NWn5SFlwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlS4TWM2OD1yLkO4O|AyKM7:TR?= NIn2U5FUSU6JRWK=
MONO-MAC-6 M4LTWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33jPGlEPTB;MD6zPFc4PiEQvF2= MofyV2FPT0WU
SK-MM-2 NVu5fpJiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTBwM{m4Olgh|ryP M1u4c3NCVkeHUh?=
CHP-126 NVX3VJVxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPKflZKSzVyPUCuOFAzOzFizszN NEjwW3hUSU6JRWK=
A101D MoLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlGyTWM2OD1yLkSwN{DPxE1? NGrHd2hUSU6JRWK=
SCH NI\F[IVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37scGlEPTB;MD60NFM1OiEQvF2= NXrkTZNsW0GQR1XS
NMC-G1 MnrNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXl[|hKSzVyPUCuOFA{PjdizszN M4\qV3NCVkeHUh?=
NCI-H209 M{LRdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDVeHh6UUN3ME2wMlQxPjF|IN88US=> NHrDO4pUSU6JRWK=
MOLT-16 M3zxO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHi3cYxKSzVyPUCuOFExOTdizszN M1zFUHNCVkeHUh?=
RPMI-6666 Mk\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX60U5VYUUN3ME2wMlQyOTJizszN NVzCV2cxW0GQR1XS
OPM-2 NVLHXWJbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXPTWM2OD1yLkSxOVE{KM7:TR?= MXLTRW5ITVJ?
MRK-nu-1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\3W2lEPTB;MD60N|E2OyEQvF2= NYrGWIJvW0GQR1XS
BC-1 NHPje2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnH3TWM2OD1yLkSzOFA{KM7:TR?= NILOeXRUSU6JRWK=
MHH-NB-11 MnXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vZN2lEPTB;MD60N|Q2OyEQvF2= MmfkV2FPT0WU
Ramos-2G6-4C10 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXMeWtKSzVyPUCuOFM5QTdizszN NUnYb|hOW0GQR1XS
LS-513 M4\6TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTBwNES1NFEh|ryP MULTRW5ITVJ?
K5 NHrhSmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrXTWM2OD1yLkS3NFI2KM7:TR?= MXfTRW5ITVJ?
HOP-62 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4njfWlEPTB;MD60PFM2QCEQvF2= NHXQeJRUSU6JRWK=
NCI-H187 M4\Vc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWi3UXdKUUN3ME2wMlQ6OjJ5IN88US=> NWSzRY9iW0GQR1XS
BE-13 NVPDSFZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjQco81UUN3ME2wMlQ6PjZzIN88US=> NH\WVphUSU6JRWK=
HC-1 M1LrbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlO4TWM2OD1yLkWwOFc{KM7:TR?= M4HhNnNCVkeHUh?=
ACN M17tb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTBwNUGwNlgh|ryP NVLlRVFHW0GQR1XS
HCC1599 NG\VfGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTBwNUG1O{DPxE1? MnfhV2FPT0WU
MV-4-11 M2jSbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PHZ2lEPTB;MD61N|A1OSEQvF2= MlnnV2FPT0WU
LC-2-ad NXHEflFLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTBwNUO2OlMh|ryP M{fFcXNCVkeHUh?=
HL-60 NWnSb5BIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrRZYZKSzVyPUCuOVQzPjFizszN Mmj3V2FPT0WU
NB17 M4XydGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYn4PWhUUUN3ME2wMlU1OzhizszN NGn0PIRUSU6JRWK=
TE-1 MmHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2qxXWlEPTB;MD61OVMxPiEQvF2= M13ObXNCVkeHUh?=
NCI-H524 Mme4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFj6RlhKSzVyPUCuOVU1ODFizszN MXjTRW5ITVJ?
MZ7-mel Mn3nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\VTHBKSzVyPUCuOVYyODVizszN NIDEfYhUSU6JRWK=
L-363 M1jVRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrnUnZPUUN3ME2wMlU3PjV5IN88US=> NEjBTJJUSU6JRWK=
BL-41 MkPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrCU5BYUUN3ME2wMlU3QDh7IN88US=> NXfQOIJvW0GQR1XS
LU-134-A M3zQW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTBwNUewO|Mh|ryP Mlq4V2FPT0WU
SIG-M5 M4nWOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXWwSJdWUUN3ME2wMlU4QDR6IN88US=> MkfGV2FPT0WU
ONS-76 NIrvcW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWi0[FJyUUN3ME2wMlU5OjR{IN88US=> MoK0V2FPT0WU
KARPAS-299 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fXXmlEPTB;MD61PFUxPCEQvF2= MnLiV2FPT0WU
DU-4475 NV7WeGJZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTpTWM2OD1yLkW4O|A{KM7:TR?= Mo\IV2FPT0WU
NB69 NXnLfGZqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TT[GlEPTB;MD61PVgzPSEQvF2= MoXxV2FPT0WU
MHH-PREB-1 M3Plcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTBwNkC3NVkh|ryP MmDIV2FPT0WU
LU-165 NFe0d21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWL2NGpqUUN3ME2wMlYyQDF{IN88US=> NGSwXXBUSU6JRWK=
LOUCY M2jXfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTBwNkOzOlQh|ryP NXvtVWFJW0GQR1XS
NCI-H526 NVLMfmczT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTBwNkO1OFEh|ryP NV7zdndmW0GQR1XS
KE-37 M{nBZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTOSo9KSzVyPUCuOlQzPzZizszN MnO3V2FPT0WU
NALM-6 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DZfWlEPTB;MD62OFg3KM7:TR?= MYnTRW5ITVJ?
CW-2 M364RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\5T4hyUUN3ME2wMlY2Pzl2IN88US=> M1fVVHNCVkeHUh?=
SU-DHL-1 Mof6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LKSWlEPTB;MD62OVk1PyEQvF2= MUfTRW5ITVJ?
NB13 NXWyN455T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTNR49HUUN3ME2wMlY3QDF5IN88US=> MUPTRW5ITVJ?
QIMR-WIL NV\2SYE{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTBwNkizOFMh|ryP MX;TRW5ITVJ?
ECC12 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3L2emlEPTB;MD63NFA5PiEQvF2= MVnTRW5ITVJ?
KALS-1 NEGySmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLlNFhKSzVyPUCuO|A1QTJizszN MlHTV2FPT0WU
COR-L279 M3XSZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojBTWM2OD1yLkewPVk3KM7:TR?= MnLRV2FPT0WU
NB14 M3zJOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTBwN{K2NVch|ryP MXnTRW5ITVJ?
CCRF-CEM MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;zfnk1UUN3ME2wMlc1PjZzIN88US=> NX75bZNEW0GQR1XS
SW954 MojIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33GcWlEPTB;MD63OVk6QSEQvF2= MVXTRW5ITVJ?
IST-SL1 NGLwZmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHuTWM2OD1yLke3N|Q5KM7:TR?= Mnj0V2FPT0WU
LAMA-84 NHHPdXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmT0TWM2OD1yLke3OVY4KM7:TR?= NF7IdZpUSU6JRWK=
Daudi MkfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkT3TWM2OD1yLke3OlgyKM7:TR?= NFr0OpZUSU6JRWK=
BC-3 MlTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFu5cZFKSzVyPUCuO|g{ODhizszN NV\6TXg1W0GQR1XS
HCC2998 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HlUGlEPTB;MD63PFM3KM7:TR?= NGm4SJJUSU6JRWK=
NCI-H69 NXnSNnVXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTBwOECxOFch|ryP M3;oZnNCVkeHUh?=
CPC-N NV3ITmIxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1K3dmlEPTB;MD64NFUzPCEQvF2= Ml7OV2FPT0WU
NOMO-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLuTWM2OD1yLkixNFg1KM7:TR?= MnnhV2FPT0WU
CESS NFzqOXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTBwOEGxPVch|ryP MlH2V2FPT0WU
LC4-1 NHHuWXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX[wOmNrUUN3ME2wMlg1ODB5IN88US=> NVXhcJNLW0GQR1XS
BL-70 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7TW5RKSzVyPUCuPFU4ODJizszN NX3yNop5W0GQR1XS
ES4 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTBwOEW4Olgh|ryP NFu2NW1USU6JRWK=
HCE-T NUPVemRHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTBwOEexO|Eh|ryP MojwV2FPT0WU
JAR MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXITWM2OD1yLki3PFI4KM7:TR?= MV3TRW5ITVJ?
ST486 NHLMbo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3e0cmlEPTB;MD64O|kyPyEQvF2= NUD6Wmc6W0GQR1XS
KS-1 NYDlbXdyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTBwOEiwPVYh|ryP NHTtU4VUSU6JRWK=
GDM-1 NUTueHFjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnW1TWM2OD1yLki4Olg4KM7:TR?= NELBUmZUSU6JRWK=
EHEB MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfoWXpKSzVyPUCuPVI2QDVizszN MV7TRW5ITVJ?
LB2518-MEL MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXWTWM2OD1yLkmzNlg1KM7:TR?= MV;TRW5ITVJ?
GOTO NIn0WoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTBwOUWwO|Yh|ryP M2XWSHNCVkeHUh?=
LXF-289 M3fsZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTBwOUW5NFEh|ryP M4DucnNCVkeHUh?=
ES6 M4fFOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTBwOU[0N|ch|ryP MYjTRW5ITVJ?
OS-RC-2 Mnr1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjmTWM2OD1yLkm2PFMh|ryP MmrNV2FPT0WU
DMS-153 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzlTWM2OD1yLkm3OFY6KM7:TR?= MkjUV2FPT0WU
SK-PN-DW NVrtNGVwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7NTW1KSzVyPUCuPVc5OzFizszN MVPTRW5ITVJ?
HH NXG0cHI1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPZTWM2OD1yLkm4PVU6KM7:TR?= MlzEV2FPT0WU
SH-4 M37xb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmC4TWM2OD1zLkCyOFEh|ryP MnHpV2FPT0WU
MOLT-4 Mn3US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfrVolKSzVyPUGuNFM1PTRizszN MVHTRW5ITVJ?
TGW NYfINnpDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTm[WhGUUN3ME2xMlA4Pjd3IN88US=> M2XGPHNCVkeHUh?=
L-540 NH;vO4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HSfWlEPTB;MT6xNFYxPCEQvF2= NIjLSHdUSU6JRWK=
PF-382 NUH2O5JTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrrU2lKSzVyPUGuNVE2OTNizszN M32xbXNCVkeHUh?=
LC-1F MnOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTFwMUKwNFch|ryP M3\CSXNCVkeHUh?=
OVCAR-4 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTjTWM2OD1zLkGzNVY2KM7:TR?= MYDTRW5ITVJ?
A4-Fuk MlfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTFwMUWzOlQh|ryP NVH3d3hCW0GQR1XS
HCC2218 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnn5TWM2OD1zLkG2OlQyKM7:TR?= NV3ucpRGW0GQR1XS
HAL-01 MkXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;oTWM2OD1zLkG2PVQ{KM7:TR?= MYHTRW5ITVJ?
IST-MEL1 M2K1V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXYTWtKSzVyPUGuNVc3PTlizszN MnjYV2FPT0WU
NCI-H719 NYDvR|lLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLqT5NKSzVyPUGuNVc5QThizszN NInLWGxUSU6JRWK=
EVSA-T MojpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTFwMUixNVQh|ryP MXjTRW5ITVJ?
SK-NEP-1 NFjvN|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIi2VWNKSzVyPUGuNlAzPjZizszN NVz1OHhPW0GQR1XS
OCUB-M NFPofHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PVeWlEPTB;MT6yNVQ5QSEQvF2= NYnseIRtW0GQR1XS
MEG-01 M1PkN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWH0VJE2UUN3ME2xMlIzOTF6IN88US=> NVzLN|AzW0GQR1XS
no-10 NET0V4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jI[WlEPTB;MT6yN|EyOiEQvF2= MXnTRW5ITVJ?
MHH-CALL-2 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTFwMkS3NlEh|ryP NWC1SGNLW0GQR1XS
SK-N-DZ MmO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HZWWlEPTB;MT6yOFc4PiEQvF2= NX[wcWxLW0GQR1XS
SCLC-21H NGm3ZmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vKWmlEPTB;MT6yOlQ4QCEQvF2= NX3VUmhHW0GQR1XS
CTV-1 M37Ne2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHMTZlQUUN3ME2xMlI4PDJ3IN88US=> NILZ[|hUSU6JRWK=
NB1 M2nn[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDPZZhVUUN3ME2xMlI4PzN{IN88US=> NIj0ZnpUSU6JRWK=
NCI-H64 NWDy[3pWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXW3[4o{UUN3ME2xMlI5PDZ{IN88US=> NEHofXVUSU6JRWK=
MDA-MB-134-VI M{Ppcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfhdHQ5UUN3ME2xMlI5PTd5IN88US=> MYfTRW5ITVJ?
LB2241-RCC MlXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlq1TWM2OD1zLkK4OlY{KM7:TR?= Mk\sV2FPT0WU
8-MG-BA MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjWOmtKSzVyPUGuNlg5PjZizszN MonSV2FPT0WU
LP-1 NWDvbZpPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfYW3JKSzVyPUGuNlk6PDdizszN M3rRXXNCVkeHUh?=
LS-411N NHPJSG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1j2Z2lEPTB;MT6zNFk6QCEQvF2= NHTHWJpUSU6JRWK=
CAL-148 M{P2PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVT0ZYtGUUN3ME2xMlMzPTR{IN88US=> NXr5XnM2W0GQR1XS
NCI-H2171 NITYZXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTFwM{S1NFIh|ryP MlfvV2FPT0WU
JiyoyeP-2003 MoPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTFwM{WzPUDPxE1? NU\pWYR7W0GQR1XS
NCI-H2107 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLkd3pKSzVyPUGuN|U5QDNizszN M1nXS3NCVkeHUh?=
BB30-HNC M3zpdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfSTWM2OD1zLkO4PVc5KM7:TR?= M4TSRXNCVkeHUh?=
K-562 NWnZWmwxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLrTWM2OD1zLkO5NlE6KM7:TR?= NFfnTIVUSU6JRWK=
PSN1 NHHveIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoS4TWM2OD1zLkSyNlg4KM7:TR?= MVjTRW5ITVJ?
HCC2157 M{XiUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zZ[2lEPTB;MT60NlY6OSEQvF2= NYi3fIZ4W0GQR1XS
SBC-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTFwNEK3OFEh|ryP NVLqRow3W0GQR1XS
MC116 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\1blFRUUN3ME2xMlQ{PjF3IN88US=> MY\TRW5ITVJ?
KARPAS-422 MmfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HxUGlEPTB;MT60OVM2QCEQvF2= M{TwT3NCVkeHUh?=
LB996-RCC NEnyN|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTFwNEexNFMh|ryP NHPUNoFUSU6JRWK=
MSTO-211H NXzHZnFYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTFwNEe5PFch|ryP MX;TRW5ITVJ?
BT-474 NUPB[Y03T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrMTWM2OD1zLkWxO|Y1KM7:TR?= Mn\FV2FPT0WU
A388 MmXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTFwNUG5OFUh|ryP NFPwXmFUSU6JRWK=
SJSA-1 MmnMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfRTWM2OD1zLkWyNlYh|ryP MYTTRW5ITVJ?
COLO-829 M3zQS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvkcYZKSzVyPUGuOVM2PjRizszN NUW3ZXh2W0GQR1XS
KM-H2 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTFwNU[2O{DPxE1? M2r0NnNCVkeHUh?=
GR-ST MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTFwNU[4NkDPxE1? MlH0V2FPT0WU
RPMI-8866 NGjDXlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3ToUWlEPTB;MT62NFE1PCEQvF2= NEjwT5JUSU6JRWK=
KG-1 NFXzcVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjVOFh1UUN3ME2xMlYyQTBzIN88US=> M2rNdHNCVkeHUh?=
NCI-H82 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTFwNkO0NFYh|ryP M4f2VnNCVkeHUh?=
LB1047-RCC NF3hb4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XMUmlEPTB;MT62N|Q2QSEQvF2= NXzlTGlvW0GQR1XS
KM12 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfrTHRKSzVyPUGuOlQ4KM7:TR?= NXnXW4toW0GQR1XS
NB5 MkjUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTFwNkW2O|ch|ryP M3XNWXNCVkeHUh?=
HDLM-2 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4q4dWlEPTB;MT62PFI5OSEQvF2= M{jNVHNCVkeHUh?=
KU812 NX6zZ2l7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV30O4g{UUN3ME2xMlY6PjB3IN88US=> MWnTRW5ITVJ?
DB NXPKb5R6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PRSGlEPTB;MT63NFM2OyEQvF2= NEXmSlZUSU6JRWK=
HD-MY-Z NHPUPFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVywWo1wUUN3ME2xMlc2OjN2IN88US=> M3zXfHNCVkeHUh?=
KURAMOCHI NUnXcpZkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlK5TWM2OD1zLke3NlA4KM7:TR?= M3\hcHNCVkeHUh?=
ETK-1 NXrvZXZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnKeIN3UUN3ME2xMlc5QDd7IN88US=> M1frdXNCVkeHUh?=
SK-UT-1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\M[IxKSzVyPUGuO|k{QDhizszN M2K0cHNCVkeHUh?=
HUTU-80 NUX5fGRxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvRTWM2OD1zLke5OVA5KM7:TR?= M2jxWXNCVkeHUh?=
ES7 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHP3fVBKSzVyPUGuPFA{ODJizszN NVf3U3JRW0GQR1XS
SW872 MkK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWWwTHVEUUN3ME2xMlgyOzl3IN88US=> MkTJV2FPT0WU
TK10 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjzN45KUUN3ME2xMlg{OTB6IN88US=> M3m5cnNCVkeHUh?=
LB831-BLC NF;CNYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlH6TWM2OD1zLkizOVY{KM7:TR?= NV21U3MzW0GQR1XS
TE-9 M1fGNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTFwOES0NlIh|ryP NXTYVnoyW0GQR1XS
MLMA MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnNN2RKSzVyPUGuPFgzOzRizszN Mny1V2FPT0WU
D-542MG MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfoWHBKSzVyPUGuPFk{PzNizszN M3exbHNCVkeHUh?=
EW-16 NI\GdI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTFwOUK3NkDPxE1? NEDOS3FUSU6JRWK=
LOXIMVI NEP5bJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTFwOUOyPEDPxE1? MWTTRW5ITVJ?
GB-1 M1;DN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX63SFZ1UUN3ME2xMlk{QDZ4IN88US=> M1nXN3NCVkeHUh?=
IST-SL2 NX7aNHBKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn[yTWM2OD1{LkCwNlYzKM7:TR?= MkDvV2FPT0WU
LAN-6 M3zDWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrHTng6UUN3ME2yMlAyQTZ4IN88US=> M{\JOXNCVkeHUh?=
NCI-H510A NVTBPVhzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTi[JNKUUN3ME2yMlA1PTB{IN88US=> NVvvNlBoW0GQR1XS
NCI-H1092 NWG0NZIzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXr[WRtUUN3ME2yMlA2OTJ2IN88US=> NVXjS4tuW0GQR1XS
HT MmjxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3JUoNxUUN3ME2yMlExPDV2IN88US=> MlnkV2FPT0WU
RL95-2 MnzOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjuTWM2OD1{LkGxOFgzKM7:TR?= NWXVZ2Q2W0GQR1XS
NCI-H1355 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFz6ZlhKSzVyPUKuNVE4QTJizszN MmDoV2FPT0WU
NCI-H720 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfPTWM2OD1{LkG2PFc{KM7:TR?= MXXTRW5ITVJ?
NCI-H1522 M4Xtdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTJwMkG3NlMh|ryP Mke4V2FPT0WU
LB373-MEL-D MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4j3bGlEPTB;Mj6yOlkxOiEQvF2= MnnEV2FPT0WU
DG-75 NHzqS|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTJwMkexOFgh|ryP MUDTRW5ITVJ?
ML-2 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrzOXVQUUN3ME2yMlMzQDV3IN88US=> M3fZPHNCVkeHUh?=
SF126 NVizNlZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTJwM{OwPVQh|ryP M3njUHNCVkeHUh?=
MPP-89 M13zOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfDeWpKSzVyPUKuN|MyPDVizszN MVjTRW5ITVJ?
NCI-H345 M17jWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXwbGlqUUN3ME2yMlM{Ojd5IN88US=> MV7TRW5ITVJ?
LS-123 MmPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWj6VG9nUUN3ME2yMlM1QTN4IN88US=> M{DWNnNCVkeHUh?=
NB10 MnHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTJwNEGwPVIh|ryP MXXTRW5ITVJ?
CGTH-W-1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYf6SId3UUN3ME2yMlQzOjZ5IN88US=> NVXpXGhZW0GQR1XS
CP66-MEL NVnuWIFHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTJwNEe3O{DPxE1? M2D2eHNCVkeHUh?=
L-428 M3rlWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3hSpFuUUN3ME2yMlQ5PTJzIN88US=> NVnHPZZWW0GQR1XS
DMS-79 MnLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTJwNUSxNFMh|ryP Ml\jV2FPT0WU
NCI-H1882 NFu2d5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTJwNke1OlIh|ryP MXPTRW5ITVJ?
KGN MnHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1K1U2lEPTB;Mj63Olg4PiEQvF2= M1TKTHNCVkeHUh?=
EW-1 NV7N[5Z1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTJwN{ewPFMh|ryP MXzTRW5ITVJ?
U-266 MnfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTOWmh4UUN3ME2yMlg1QDJ|IN88US=> NXrTNY86W0GQR1XS
COLO-320-HSR NEPWR3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrsTWM2OD1{Lki1OlQyKM7:TR?= NUjLTYN6W0GQR1XS
KMOE-2 NFjkUIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPzTWM2OD1{Lki3O|EyKM7:TR?= M3vsZ3NCVkeHUh?=
BB49-HNC MmS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnSTWM2OD1{LkmyOFgh|ryP NF;RZ2lUSU6JRWK=
GI-1 NXfwfJhKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTJwOUK5OVch|ryP NHTY[2pUSU6JRWK=
NCI-H1304 NIS3W4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3zTWM2OD1|LkCwOVEyKM7:TR?= MYjTRW5ITVJ?
NCI-H2227 MnHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTNwMEKwO|kh|ryP MniyV2FPT0WU
U-87-MG NIjQbFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTNwMEO1NVMh|ryP NI\ESnpUSU6JRWK=
NCI-H747 NVX1fnpUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjXU4dKSzVyPUOuNFUzODZizszN M{PjOnNCVkeHUh?=
CTB-1 M1zXcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXuU3B[UUN3ME2zMlA2Ozd4IN88US=> M{TVcXNCVkeHUh?=
RPMI-8226 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvzfXpKSzVyPUOuNVQ{PzhizszN NXLpTYRnW0GQR1XS
NCI-H2141 NEXF[VRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PFfWlEPTB;Mz6xOlU3PiEQvF2= M4\ienNCVkeHUh?=
IST-MES1 MkfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV24UGdmUUN3ME2zMlE5Ojd7IN88US=> NWLLeoJYW0GQR1XS
TE-5 M3Xkb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXf2WldWUUN3ME2zMlIyOzR{IN88US=> M2jlWXNCVkeHUh?=
UACC-257 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37JeGlEPTB;Mz60N|Y2QSEQvF2= MUXTRW5ITVJ?
SK-N-FI NYPj[Wp7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vySGlEPTB;Mz60OVIzPyEQvF2= NUjzXVR[W0GQR1XS
MFH-ino NYnZemY{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfzTWM2OD1|LkS2OVg6KM7:TR?= NEXJc4NUSU6JRWK=
SF268 M1\Idmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTuTWM2OD1|LkS4NVc1KM7:TR?= M{\OPXNCVkeHUh?=
TE-12 NIi0fHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTNwNUG2PVkh|ryP NGPM[I1USU6JRWK=
NB6 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXvTWM2OD1|LkW1OVY{KM7:TR?= MknRV2FPT0WU
DJM-1 NHfXb2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXXO2xZUUN3ME2zMlU6QDl7IN88US=> NWnmWWg4W0GQR1XS
MZ1-PC M4Dsb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NET3[Y5KSzVyPUOuOlE3OjRizszN NFeyVZlUSU6JRWK=
OCI-AML2 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2POcWlEPTB;Mz62NlY4OSEQvF2= NInFboRUSU6JRWK=
NCI-H1155 NGPhT3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXnOHdPUUN3ME2zMlcxQTR5IN88US=> NIPPd49USU6JRWK=
RKO MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrsTWM2OD1|Lke3NVg6KM7:TR?= MoDKV2FPT0WU
ECC4 M3GxNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjZU4pKSzVyPUOuPVcyQTVizszN MW\TRW5ITVJ?
BB65-RCC NXzNZolZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEflOm5KSzVyPUOuPVc2PDdizszN Mk\2V2FPT0WU
EB-3 MmrxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfvWHdKSzVyPUOuPVk3OzNizszN NEPGfJpUSU6JRWK=
SHP-77 M{jTbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTRwMEC1NlQh|ryP MlzCV2FPT0WU
NCI-H2196 NEjYTJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnOTWM2OD12LkC1OlI2KM7:TR?= MUnTRW5ITVJ?
GI-ME-N M3P1Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XQTmlEPTB;ND6wOlM6QSEQvF2= MX3TRW5ITVJ?
MN-60 M{PmSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTRwMUC4O{DPxE1? NEnocHpUSU6JRWK=
NCI-H1694 NYPmN2luT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zKRWlEPTB;ND6xN|QxPSEQvF2= MnHYV2FPT0WU
LU-65 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HWS2lEPTB;ND6xOVM{OiEQvF2= MoLGV2FPT0WU
NCI-H1436 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLFWVM1UUN3ME20MlE5OzN|IN88US=> M3;UNHNCVkeHUh?=
KINGS-1 M3mwSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PYNWlEPTB;ND6zNVQ{OiEQvF2= NE\SRlJUSU6JRWK=
GT3TKB M3T4[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7tdJlXUUN3ME20MlM{OjZ6IN88US=> NVPnO5F4W0GQR1XS
Becker MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHkTWhKSzVyPUSuN|c{OTJizszN M2Oy[nNCVkeHUh?=
HCC1187 NELnN2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnHTWM2OD12Lki5OlU4KM7:TR?= MmLrV2FPT0WU
D-502MG NF7nRZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nj[WlEPTB;NT6wNFQyPiEQvF2= NVG5NJpMW0GQR1XS
VA-ES-BJ NITNWYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofFTWM2OD13LkGzO|c5KM7:TR?= MX;TRW5ITVJ?
NB7 NVn5OItlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1X6TmlEPTB;NT6xOFEyOiEQvF2= Ml\KV2FPT0WU
SW962 M4PPT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rGb2lEPTB;NT6zPFgyPCEQvF2= M4DFWHNCVkeHUh?=
no-11 NFrRXmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTVwN{[zOFMh|ryP M1rPZnNCVkeHUh?=
KNS-81-FD NUi2W2RFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmT5TWM2OD13LkmwOlk1KM7:TR?= NUezRWNMW0GQR1XS
COLO-684 MoixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NES5U2JKSzVyPUWuPVk1QTRizszN M{XkeXNCVkeHUh?=
D-263MG MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nWcmlEPTB;Nj6wPFg6PSEQvF2= NFPBZVJUSU6JRWK=
EW-24 M4rY[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vyV2lEPTB;Nj6yPFUyKM7:TR?= NITpdJRUSU6JRWK=
TE-10 M3vRcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnaPGRDUUN3ME22MlQzPjJ|IN88US=> NVnkbIE3W0GQR1XS
EKVX NXjRNVhHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;HTWM2OD14LkS2N|IyKM7:TR?= NI\CO|RUSU6JRWK=
NCI-H1648 NYLDZ3ZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTZwNke1OVch|ryP M2fRXHNCVkeHUh?=
LB771-HNC MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7Qd4FKSzVyPU[uPVI{ODFizszN M2DXUHNCVkeHUh?=
SK-MEL-1 NVjWbJF4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXqXHdDUUN3ME24MlE{OTZ4IN88US=> NG\6Z5hUSU6JRWK=
COLO-668 NW[1T2c2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRThwMke3PFYh|ryP MXzTRW5ITVJ?
EW-12 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjEb25iUUN3ME24MlQxQDB|IN88US=> NFrlWIZUSU6JRWK=
A253 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRThwOES2OlEh|ryP NIC5eWFUSU6JRWK=
NCI-H2126 NITqXZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\YcmpVUUN3ME24Mlg6OzF7IN88US=> MknrV2FPT0WU
Calu-6 NXPCeo5oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDlUoV{UUN3ME24Mlk6ODR{IN88US=> NYexTVc1W0GQR1XS
NCI-H23 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nRNWlEPTB;OT6xO|c1PiEQvF2= M3vk[HNCVkeHUh?=
WSU-NHL NEHrdWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\aRXFKSzVyPUmuO|c1PzhizszN NVPQTZE1W0GQR1XS
MMAC-SF NHnoTVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jvPGlEPTB;OT65O|kxPCEQvF2= MWXTRW5ITVJ?
SK-LMS-1 Mkn6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELXU4ZKSzVyPUGwMlI5OzRizszN M4S0S3NCVkeHUh?=
GCIY M2H5WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17WPGlEPTB;MUCuOVkzPCEQvF2= M{jBb3NCVkeHUh?=
TE-15 NEnaTWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PlV2lEPTB;MUGuOlAxPCEQvF2= MVrTRW5ITVJ?
EoL-1-cell NH3xfG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrITWM2OD1zMT63OlgzKM7:TR?= M4TXS3NCVkeHUh?=
NCI-H2081 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPkXo5KSzVyPUGxMlc4QDZizszN NUj1So04W0GQR1XS
EW-3 NUfpUoN2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTF{LkK0OlMh|ryP M3LlcXNCVkeHUh?=
CAS-1 Ml\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vqT2lEPTB;MUKuN|Y{OSEQvF2= M1ywbnNCVkeHUh?=
C2BBe1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIm0dJhKSzVyPUGyMlYyOzFizszN NWXiXHJmW0GQR1XS
D-247MG NXvBWVk6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTaSY9uUUN3ME2xNk44QTV{IN88US=> MYfTRW5ITVJ?
NCI-SNU-5 NVm1eYdvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nEUWlEPTB;MUKuPFAyOyEQvF2= M{XYe3NCVkeHUh?=
LS-1034 MoqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFe1XZdKSzVyPUG0MlM6PzVizszN M2rlN3NCVkeHUh?=
EW-18 MmjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjnZWtmUUN3ME2xOE41PDhizszN MXrTRW5ITVJ?
Raji NUDldFJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoThTWM2OD1zND61NFQ6KM7:TR?= NIT6RYFUSU6JRWK=
D-283MED NH\tNoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\Ce4ZKSzVyPUG0MlYzPzFizszN MXTTRW5ITVJ?
MZ2-MEL NHPzNYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTLTWM2OD1zND65Olk3KM7:TR?= MoK1V2FPT0WU
NCI-SNU-16 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTQTWM2OD1zNT60OlM{KM7:TR?= MmLPV2FPT0WU
P30-OHK MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTjTWM2OD1zNz63PFMyKM7:TR?= MmmyV2FPT0WU
RXF393 MonQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1m4bmlEPTB;MUmuNFE5PiEQvF2= NFzaR3pUSU6JRWK=
NCI-H1395 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVOwZZBJUUN3ME2yNE43PzB|IN88US=> MUXTRW5ITVJ?
U-698-M NEDJeYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\hTWM2OD1{MD63NFc2KM7:TR?= M2[yRnNCVkeHUh?=
NCI-SNU-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\QXGNKSzVyPUKwMlczOjNizszN MYXTRW5ITVJ?
SW684 NVfpVI5LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\nTWM2OD1{MT6xO|E3KM7:TR?= NEXsdHRUSU6JRWK=
NCI-H716 M{LvbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3hO41KSzVyPUKxMlMyPTRizszN NILYSoFUSU6JRWK=
JVM-2 MoLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrXTWM2OD1{MT60NVM{KM7:TR?= MmDEV2FPT0WU
NCI-H1581 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTJ{LkSxOFgh|ryP NFPsSY5USU6JRWK=
CA46 NHzX[HJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zRWmlEPTB;M{GuOlk{PiEQvF2= M{XnU3NCVkeHUh?=
SNB75 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEC0W5JKSzVyPUOzMlY2ODNizszN NVXNcm5pW0GQR1XS
KNS-42 M2TzbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4H4VmlEPTB;M{WuPVYzPCEQvF2= NXfGNJp1W0GQR1XS
TUR NUjxSXRzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTN4LkC1NlEh|ryP M1niSnNCVkeHUh?=
REH M1rvfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;MTWM2OD1|Nz64NlEyKM7:TR?= NYO3W|VjW0GQR1XS
EW-22 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{j3ZmlEPTB;NEKuNlg5PSEQvF2= NXPWPIlWW0GQR1XS
NCI-H446 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4Cwe2lEPTB;NEKuO|g2OyEQvF2= M{XMWXNCVkeHUh?=
ES3 NYHYdlRnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHq0bWVKSzVyPUSzMlE{OzlizszN MXnTRW5ITVJ?
EW-11 NWjyW4VrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfnfGlKSzVyPUS0MlgzOThizszN MkLLV2FPT0WU
RH-1 MnjyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlL1TWM2OD12Nz61PFEzKM7:TR?= MnnsV2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo MS-275 exhibits great antitumor activity against human tumor xenografts except HCT-15 at 49 mg/kg. [1] MS-275 demonstrates promising therapeutic potential in both solid and hematologic malignancies, as well as regulation of physiologic and aberrant gene expression. [4] MS-275, combination with IL-2, has great antitumor activity to renal cell carcinoma xenograft model, which due to decreased T regulatory cells and increased splenocytes. [5]

Protocol

Kinase Assay:

[6]

+ Expand

Standard HDAC Assays:

Rat liver enzyme is diluted 1:6 with HDAC buffer. Recombinant human HDACs are diluted 1:4 in HDAC buffer. For standard HDAC assays, 60 μL of HDAC buffer is mixed with 10 μL of diluted enzyme solution at 30 °C. The HDAC reaction is started by adding 30 μL substrate solution in HDAC buffer followed by 30 min of incubation at 30 °C. The reaction is stopped by adding 100 μL trypsin solutions (10 mg/ml trypsin in 50 mM Tris-HCl [pH 8.0], 100 mM NaCl, 2 μM TSA). After a 20 min incubation period at 30 °C, the release of AMC is monitored by measuring the fluorescence at 460 nm (λex = 390 nm). Fluorescence intensity is calibrated using free AMC. For standard time course experiments, 20 pmol of substrate is used in the initial 100 μL HDAC reaction. Km and Vmax values are determined by measuring the fluorescence AMC generated by enzymatic cleavage of 2–50 pmol of substrate. The experimental data are analyzed using a Hanes plot. The AMC signals are recorded against a blank with buffer and substrate but without the enzyme.
Cell Research:

[2]

+ Expand
  • Cell lines: A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 cells
  • Concentrations: ~ 10 μM
  • Incubation Time: 3 days
  • Method:

    Cancer cells (5 × 103) are seeded into each well of 96-well plates and cultured with graded concentrations of MS-275 for 3 days. The cells are stained with 0.1 mg/mL neutral red for 1 hour in a CO2-incubator, and, after aspiration of the medium, OD540 of the neutral red solubilized with 50 μL of ethanol and 150 μL of 0.1 M Na2HPO4 is measured. The IC50 value is determined by plotting growth inhibition of the cells against the logarithm of the drug concentration.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: A2780, HT-29, HTC-15, KB-3-1, 4-1St, St-4, Capan-1 and Calu-3 cells are injected subcutaneously into the flank of nude mice.
  • Formulation: Dissolved with 0.05 N HCl, 0.1% Tween 80
  • Dosages: 12.3, 24.5 and 49 mg/kg
  • Administration: Administered orally once daily 5 days per week for 4 weeks
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 75 mg/mL (199.25 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 376.41
Formula

C21H20N4O3

CAS No. 209783-80-2
Storage powder
in solvent
Synonyms SNDX-275

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03838042 Not yet recruiting CNS Tumor|Solid Tumor University Hospital Heidelberg|German Cancer Research Center March 2019 Phase 1|Phase 2
NCT03829930 Not yet recruiting Prostate Adenocarcinoma George Washington University March 1 2019 Phase 1
NCT03765229 Recruiting Melanoma UNC Lineberger Comprehensive Cancer Center|Syndax Pharmaceuticals Inc. March 2019 Phase 2
NCT03838042 Not yet recruiting CNS Tumor|Solid Tumor University Hospital Heidelberg|German Cancer Research Center March 2019 Phase 1|Phase 2
NCT03829930 Not yet recruiting Prostate Adenocarcinoma George Washington University March 1 2019 Phase 1
NCT03765229 Recruiting Melanoma UNC Lineberger Comprehensive Cancer Center|Syndax Pharmaceuticals Inc. March 2019 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I would like to use Entinostat(Catalog No.S1053) for animal study. What is your recommendation for the solvent? What is the role of PEG 300 in this case? Can I use DMSO only and dilute it with PBS or HBSS?

  • Answer:

    2%DMSO/30%PEG/68%Water is recommended. PEG is an important polymer that helps with the solubility of hydrophobic drugs. If you use DMSO only and dilute it with PBS or HBSS, Entinostat will likely to precipitate out since it has very low solubility in water.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products5

Tags: buy Entinostat (MS-275) | Entinostat (MS-275) supplier | purchase Entinostat (MS-275) | Entinostat (MS-275) cost | Entinostat (MS-275) manufacturer | order Entinostat (MS-275) | Entinostat (MS-275) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID